GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Liquidia Corp (NAS:LQDA) » Definitions » 5-Year Yield-on-Cost %

LQDA (Liquidia) 5-Year Yield-on-Cost % : 0.00 (As of Dec. 14, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Liquidia 5-Year Yield-on-Cost %?

Liquidia's yield on cost for the quarter that ended in Sep. 2024 was 0.00.


The historical rank and industry rank for Liquidia's 5-Year Yield-on-Cost % or its related term are showing as below:



LQDA's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.57
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of Liquidia's 5-Year Yield-on-Cost %

For the Biotechnology subindustry, Liquidia's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Liquidia's 5-Year Yield-on-Cost % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Liquidia's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Liquidia's 5-Year Yield-on-Cost % falls into.



Liquidia 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Liquidia is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5

Liquidia  (NAS:LQDA) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Liquidia 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of Liquidia's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.


Liquidia Business Description

Traded in Other Exchanges
Address
419 Davis Drive, Suite 100, Morrisville, NC, USA, 27560
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.
Executives
Scott Moomaw officer: SVP, Commercial P.O. BOX 110085, RESEARCH TRIANGLE PARK NC 27709
Michael Kaseta officer: Chief Financial Officer 7100 WEST CREDIT AVENUE, SUITE 101, MISSISSAUGA A6 L5N OE4
Russell Schundler officer: General Counsel P.O. BOX 110085, RESEARCH TRIANGLE PARK NC 27709
Jason Adair officer: V.P. Crp Dvlpmnt and Strtgy C/O LIQUIDIA TECHNOLOGIES, INC., 419 DAVIS DRIVE, SUITE 100, MORRISVILLE NC 27560
Rajeev Saggar officer: Chief Medical Officer 419 DAVIS DRIVE, SUITE 100, MORRISVILLE NC 27560
Roger Jeffs director
Paul B Manning director, 10 percent owner 200 GARRETT STREET SUITE S, CHARLOTTESVILLE VA 22902
Caligan Partners Lp director, 10 percent owner, other: See Remarks 515 MADISON AVENUE, 8TH FLOOR, NEW YORK NY 10022
Robert A Lippe officer: Chief Operations Officer C/O ALEXZA PHARMACEUTICALS, INC., 2091 STIERLIN COURT, MOUNTAIN VIEW CA 94043
Arthur S Kirsch director 7100 WEST CREDIT AVENUE, SUITE 101, C/O ARALEZ PHARMACEUTICALS INC., MISSISSAUGA A6 L5N 0E4
David Edward Johnson 10 percent owner 590 MADISON AVENUE, NEW YORK NY 10022
Raman Singh director C/O LIQUIDIA TECHNOLOGIES, INC., 419 DAVIS DRIVE, SUITE 100, MORRISVILLE NC 27560
Katherine Rielly-gauvin director 419 DAVIS DRIVE, MORRISVILLE NC 27560
Stephen M Bloch director 285 RIVERSIDE AVENUE, SUITE 250, WESTPORT CT 06880
Joanna Horobin director 215 FIRST STREET, SUITE 440, CAMBRIDGE MA 02142